News

Inpefa (sotagliflozin) is in the SGLT inhibitor class recommended as first-line treatment for heart failure by the American Heart Association and other groups. Jardiance (empaglifozin), a competitor in that class, has a list price of $570.48 for a month's supply.

Eric Hunter, president and CEO of CareOregon, and editorial advisory board member of Managed Healthcare Executive, talks with MHE about the “combination” underway between CareOrgeon and SCAN Health and how it's a good thing amid the concerns it would make CareOregon less responsive to local needs. Hunter also talks about how the combination will affect how they manage pharmacy benefits, and what else is on their radar in healthcare.